Processa Pharmaceuticals (NASDAQ: PCSA): Revolutionizing Cancer Treatment through Next-Generation Chemotherapies

Processa Pharmaceuticals’ (NASDAQ: PCSA) shares skyrocketed by over 260% from their October lows of $0.18 per share. Shares peaked at $0.65 on November 14th and more recently has consolidated around $0.43. The reason for this surge was not immediately clear given the lack of material  events. However upon digging deeper, we’ve uncovered a very interesting […]

Related Keywords

David Young ,Young ,Spectrum Pharmaceuticals Inc ,Management Team ,Questcor Pharmaceuticals ,Biodelivery Sciences International Inc ,Scilex Holding Co ,Research Development ,Sorrento Therapeutics Inc ,Nasdaq ,University Of Maryland School Pharmacy ,Scilex Pharmaceuticals Inc ,Pfizer Inc ,Alpharma Inc ,National Cancer Institute ,Processa Pharmaceutical ,Adverse Events ,Right Now ,Scilex Pharmaceuticals ,Sorrento Therapeutics ,Biodelivery Sciences International ,Spectrum Pharmaceuticals ,Chief Scientific Officer ,Acthar Gel ,Associate Professor ,Maryland School ,Clinical Pharmacology ,Trial Update ,Microcap Daily ,